Axsome Therapeutics (AXSM)
(Delayed Data from NSDQ)
$86.53 USD
+0.55 (0.64%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $86.49 -0.04 (-0.05%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$86.53 USD
+0.55 (0.64%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $86.49 -0.04 (-0.05%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum F VGM
Zacks News
Is the Options Market Predicting a Spike in Axsome (AXSM) Stock?
by Zacks Equity Research
Investors need to pay close attention to Axsome (AXSM) stock based on the movements in the options market lately.
Implied Volatility Surging for Axsome (AXSM) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Axsome (AXSM) stock based on the movements in the options market lately.
Axsome Initiates Phase III Study on Depression Candidate
by Zacks Equity Research
Axsome (AXSM) initiates phase III GEMINI study of AXS-05 for the treatment of major depressive disorder.
What's in the Cards for Fuel Tech (FTEK) in Q1 Earnings?
by Zacks Equity Research
Fuel Tech's (FTEK) Q1 results are likely to benefit from increased adoption of emission control solutions, efforts to improve sales channel and addition of a coal-fired unit in the United States.
What's in Store for Axsome (AXSM) This Earnings Season?
by Zacks Equity Research
On Axsome's (AXSM) first-quarter earnings call, investors will look for its progress with the CNS pipeline candidates and the regulatory updates on the same.
Biotech Stock Roundup: GILD Collaborates on NASH, FCSC Surges on Deal
by Zacks Equity Research
Key highlights of the past week are collaborations and pipeline updates.
Axsome's AXS-05 Meets Goal in Phase II Study, Shares Up
by Zacks Equity Research
Axsome's (AXSM) mid-stage candidate, AXS-05, achieves the primary endpoint in a phase II study as a smoking cessation treatment. Shares rise.
Implied Volatility Surging for Axsome Therapeutics (AXSM) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Axsome Therapeutics (AXSM) stock based on the movements in the options market lately.
Axsome's Depression Drug Gets Breakthrough Therapy Status
by Zacks Equity Research
Axsome (AXSM) announces that the FDA has granted Breakthrough Therapy designation to AXS-05 for the treatment of major depressive disorder (MDD).
Will Axsome Therapeutics (AXSM) Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Axsome Therapeutics Inc (AXSM).